KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Operating Expenses (2016 - 2025)

BeOne Medicines (ONC) has disclosed Operating Expenses for 11 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 11.85% to $1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 billion, a 11.71% increase, with the full-year FY2025 number at $4.2 billion, up 11.71% from a year prior.
  • Operating Expenses was $1.2 billion for Q4 2025 at BeOne Medicines, up from $1.1 billion in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $1.2 billion in Q4 2025 to a low of -$1.2 billion in Q4 2021.
  • A 5-year average of $744.7 million and a median of $822.5 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: plummeted 297.07% in 2021, then surged 148.77% in 2022.
  • BeOne Medicines' Operating Expenses stood at -$1.2 billion in 2021, then soared by 148.77% to $562.2 million in 2022, then skyrocketed by 62.27% to $912.4 million in 2023, then rose by 14.72% to $1.0 billion in 2024, then grew by 11.85% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Operating Expenses are $1.2 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.1 billion (Q2 2025).